Warning About triCitrasol

Article

Don't Infuse in Patients

ROCKVILLE, MD- The Food and Drug Administration (FDA) has issued a warning that triCitrasol may cause death when infused into patients. TriCitrasol is a 46.7% concentration of sodium citrate anticoagulant used to keep bloodlines open. A case has been discovered in which a patient died of cardiac arrest after triCitrasol was injected full strength into a hemodialysis permanent blood access catheter that had just been implanted. Rapid or excessive infusion of citrate solutions can cause fatal heart rhythm disruption, seizures, or bleeding due to loss of blood calcium.

TriCitrasol is manufactured by Cytosol Laboratories and is distributed by Medcomp. Both companies voluntarily recalled the product for use with blood access catheters. TriCitrasol is also used to prepare white cells for transfusion and is still available for that purpose.

Recent Videos
Cameron Memorial Community Hospital series with ICT  (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT  (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Isis Lamphier, MPH, MHA, CIC; Tori Whitacre Martonicz, MA; and Heather Stoltzfus, MPH, RN, CIC, at APIC Conference and Expo 2024 (Photo courtesy of Tori Whitacre Martonicz)
Lindsay K. Weir, MPH, CIC, Lead Infection Preventionist/Infection Preventionist III
•	Rebecca (Bartles) Crapanzano-Sigafoos, DrPH, MPH, CIC, FAPIC (corresponding author), executive director of APIC’s Center for Research, Practice, and Innovation, and lead author of the study.
Infection Control Today's Infection Intel: Staying Ahead With Company Updates and Product Innovations.
COVID-19 presentations at IDWeek in Las Angeles, California by Invivyd.   (Adobe Stock 333039083 by Production Perig)
Related Content